Ozempic, Wegovy, Rybelsus and the Wegovy pill: one molecule, four products
Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board
- Ozempic, Rybelsus and Wegovy all contain semaglutide, made by Novo Nordisk. The brand tells you the approved use, the form and the dose range.
- Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for weight management, cardiovascular risk reduction and a fatty liver disease, MASH.
- There are now three semaglutide tablets: Rybelsus, Ozempic tablets and Wegovy tablets. Their labels say tablets are not interchangeable milligram for milligram.
- Wegovy's label advises against using it with any other semaglutide product or GLP-1 drug.
The same molecule, different products
Semaglutide is a GLP-1 receptor agonist, an analogue with 94% sequence homology to the human hormone GLP-1 and a half-life of about a week 1; the tablets carry an absorption enhancer 2. Novo Nordisk sells it under three brand names in the US, and two of them now come in both injection and tablet form. The differences between the products are not cosmetic: each label sets out a different approved use, a different dose range and, for the tablets, a different way of taking it 1 2 3. Our semaglutide entry covers the molecule and its trials; this page compares the products.
| Product | Form | Approved for (US label) | Maintenance dose range in label |
|---|---|---|---|
| Ozempic injection | Weekly pen | Type 2 diabetes: glucose control, cardiovascular risk and kidney outcomes | 0.5 mg to 2 mg weekly |
| Rybelsus | Daily tablet | Type 2 diabetes: glucose control and cardiovascular risk | 7 mg or 14 mg daily |
| Ozempic tablets | Daily tablet | Same as Rybelsus (shared label) | 4 mg or 9 mg daily |
| Wegovy injection | Weekly pen | Obesity or overweight with a comorbidity (adults and ages 12+), cardiovascular risk, MASH | Usually 2.4 mg weekly |
| Wegovy tablets (the 'Wegovy pill') | Daily tablet | Adult obesity or overweight with a comorbidity, cardiovascular risk | 25 mg daily |
Ozempic injection: for type 2 diabetes
The Ozempic injection label lists three uses, all in adults with type 2 diabetes: to improve blood sugar control alongside diet and exercise; to reduce the risk of major cardiovascular events in those with established cardiovascular disease; and to reduce the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease 1. Weight loss is not a labelled indication 1.
It is injected once weekly, at any time of day, under the skin of the abdomen, thigh or upper arm. The label starts at 0.25 mg weekly for four weeks, then 0.5 mg, with steps to 1 mg and then 2 mg if more glucose control is needed, each after at least four weeks; for the kidney indication, the target is 1 mg. A missed dose can be taken within five days 1.
Rybelsus and Ozempic tablets: daily pills for diabetes
Rybelsus is the original oral semaglutide brand. Its current label is shared with a newer product, Ozempic tablets, and covers both. They are approved for blood sugar control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in those at high risk 2. FDA's drug shortage database lists the Rybelsus 3, 7 and 14 mg tablets as "To Be Discontinued" and says they "will be replaced by Ozempic (semaglutide) tablets" (posted June 4, 2026; re-read October 27, 2026) 4.
Both are taken once daily on an empty stomach in the morning with no more than 4 ounces of plain water, swallowed whole, and the label says to wait at least 30 minutes before eating, drinking or taking other oral medicines 2. Rybelsus starts at 3 mg daily for 30 days, a dose the label says is not effective for glucose control, then 7 mg, with an increase to 14 mg if needed. Ozempic tablets start at 1.5 mg, then 4 mg, with an increase to 9 mg if needed 2. The label states plainly that Rybelsus and Ozempic tablets are not substitutable on a milligram-to-milligram basis, and gives separate instructions for switching between them and from Ozempic injections 2.
Wegovy injection and tablets: for weight management and more
Wegovy is the semaglutide brand approved for weight management. The injection's label lists, alongside a reduced-calorie diet and more physical activity: reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight; reducing excess weight and maintaining the loss long term in adults and children aged 12 and over with obesity, and in adults with overweight and at least one weight-related condition; and treating non-cirrhotic MASH, the liver disease formerly called NASH, with moderate to advanced fibrosis, an indication granted under accelerated approval 3.
The injection starts at 0.25 mg weekly for four weeks and steps up every four weeks; the usual maintenance dose is 2.4 mg weekly, with the label giving indication-specific maintenance doses. For adult weight reduction, after at least four weeks at 2.4 mg the dose may go up to a maximum of 7.2 mg weekly (sold as Wegovy HD) if more weight loss is clinically indicated 3. Wegovy tablets, the 'Wegovy pill', are approved for adults for cardiovascular risk reduction and weight management. They start at 1.5 mg once daily for 30 days and step up every 30 days to a maintenance dose of 25 mg daily, with the same empty-stomach, water-only, 30-minute rules as the diabetes tablets 3.
Wegovy's label also carries a limitation of use: combining Wegovy tablets or injection with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended 3.
Why tablet doses are so much bigger
Semaglutide tablets are co-formulated with an absorption enhancer, SNAC (salcaprozate sodium), and are absorbed mainly in the stomach, according to the Rybelsus and Ozempic tablets label. Even so, the label estimates absolute bioavailability, the share of the dose that reaches the bloodstream, at only about 0.4% to 1% for Rybelsus 3, 7 and 14 mg, and about 1% to 2% for Ozempic tablets 1.5, 4 and 9 mg 2. The same label says the two tablets are not substitutable on a milligram-to-milligram basis 2.
The label asks for an empty stomach, no more than 4 ounces of plain water and a 30-minute wait before eating, drinking or taking other oral medicines 2. The Wegovy label adds a caution for people with type 2 diabetes taking Wegovy tablets: average semaglutide levels were lower than with the injection and more variable, so some may not reach effective levels, and the label suggests considering alternatives for those with an inadequate response 3. Each tablet has its own dose scale in its label.
Why you can't just swap them
Because they share a molecule, it is tempting to treat these products as interchangeable. The labels say otherwise in three ways. First, doses differ widely between forms: the tablets' absolute bioavailability is estimated at about 0.4% to 2% 2 3, and tablet doses run to 9, 14 or 25 mg daily while injections run from 0.25 mg to at most 7.2 mg weekly 1 3. Second, even between tablets, the label says Rybelsus and Ozempic tablets are not substitutable milligram for milligram 2. Third, each product is approved for different uses, which matters for insurance coverage and for which trials support the dose being used 1 3.
Switching between products is a prescribing decision with its own label instructions; the Rybelsus and Ozempic tablets label, for example, gives separate instructions for switching between the tablets and from Ozempic injection 2.
Self-pay prices, as of October 27, 2026
Novo Nordisk sells Wegovy directly to self-paying patients through NovoCare. Its Wegovy pricing page, read on October 27, 2026, listed Wegovy pens at $349 a month for doses from 0.25 mg to 2.4 mg, with patients new to the offer paying $199 a month for two monthly fills of the 0.25 mg or 0.5 mg doses through December 31, 2026; Wegovy HD 7.2 mg at $399 a month; and Wegovy tablets at $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg or 25 mg 5. Prices change often, and insured patients may pay very different amounts, so check the current figure before deciding.
Our cost calculator compares approved and compounded options, and our guide to compounded, branded and research tirzepatide explains why a cheaper vial is not the same product.
Which one fits, in plain terms
- Type 2 diabetes, preferring a weekly injection: Ozempic injection is the labelled option 1.
- Type 2 diabetes, preferring a daily pill and able to follow the empty-stomach routine: Rybelsus or Ozempic tablets 2.
- Weight management, cardiovascular risk with obesity, or MASH: Wegovy injection; for adults wanting a pill for weight or cardiovascular risk, Wegovy tablets 3.
- Already on one semaglutide product: do not add another, and do not combine with other GLP-1 drugs 3.
Comparing semaglutide with other drugs in the class? Our semaglutide vs tirzepatide and semaglutide vs liraglutide pages cover that.
Teenagers: only one of the products
Of all these products, only Wegovy injection is approved for anyone under 18: its weight-management indication covers children aged 12 and over with obesity, while Wegovy tablets are approved for adults 3. The label notes that patients aged 12 and older treated with the injection had higher rates of gallstones, gallbladder inflammation, low blood pressure, rash and hives than adults, and that while hypoglycaemia was more frequent in adults with type 2 diabetes and obesity on Wegovy, there are insufficient data to say whether the risk is higher in adolescents with type 2 diabetes; it asks prescribers to teach young patients the signs of low blood sugar 3. For a teenager, then, the choice is narrower than for an adult, and the follow-up matters as much as the prescription.
Shared safety points
Because the active ingredient is the same, the core safety information overlaps: stomach side effects, especially while the dose is rising, and warnings about pancreatitis, gallbladder disease and low blood sugar when combined with insulin or sulfonylureas. Wegovy's label, for example, warns that combining it with insulin or an insulin secretagogue may increase the risk of hypoglycaemia, including severe hypoglycaemia, and that those doses may need reducing 3. Our guide to peptides and blood sugar covers that interaction. Each product's full label lists its own warnings, and all three labels carry a boxed warning about thyroid C-cell tumours, which semaglutide causes in rodents; whether it does in humans is unknown 1 2 3.
Questions to ask a prescriber
- Which semaglutide product matches my diagnosis, and is it covered by my insurance for that use?
- Would a tablet suit my morning routine, given the empty-stomach and 30-minute rules?
- If I am switching products, what does the label say about the new starting dose?
- Do I take insulin or a sulfonylurea that may need adjusting?
The bottom line
Ozempic, Rybelsus and Wegovy are one molecule packaged for different jobs. Ozempic and Rybelsus are diabetes drugs; Wegovy is the weight-management, cardiovascular and MASH brand. The tablets need a strict morning routine and are not interchangeable milligram for milligram, even with each other. Choose by diagnosis and form with a prescriber, follow the label's dose steps, and never combine semaglutide products.
Frequently asked questions
Are Ozempic and Wegovy the same?
They contain the same drug, semaglutide, but Ozempic is approved for type 2 diabetes and Wegovy for weight management, cardiovascular risk reduction and MASH. Their dose ranges differ: Ozempic injection goes up to 2 mg weekly; Wegovy's usual maintenance dose is 2.4 mg, with up to 7.2 mg for adult weight reduction.
What is the difference between Rybelsus and Ozempic?
Rybelsus is a daily semaglutide tablet for type 2 diabetes; Ozempic is usually a weekly injection for the same disease. There are now also Ozempic tablets, which share Rybelsus's label but use different doses.
What is the Wegovy pill?
Wegovy tablets are daily oral semaglutide for adults with obesity or overweight and a weight-related condition, or established cardiovascular disease. They start at 1.5 mg and step up to 25 mg daily.
Can I switch from Ozempic to Wegovy?
Switching is a prescribing decision. The labels give their own starting doses, and Rybelsus and Ozempic tablets are not substitutable milligram for milligram.
Can I take two semaglutide products together?
No. Wegovy's label says combining it with other semaglutide products or any other GLP-1 drug is not recommended.
Related on Grey Peptides
- Semaglutide
- Rybelsus tablets being replaced by Ozempic tablets
- Semaglutide vs tirzepatide
- Cost calculator
Sources
- Novo Nordisk. OZEMPIC (semaglutide) injection US prescribing information, Indications and Usage, Dosage and Administration. DailyMed version 20, effective June 1, 2026 (still current on DailyMed October 27, 2026); read October 27, 2026. DailyMed
- Novo Nordisk. RYBELSUS and OZEMPIC (semaglutide) tablets US prescribing information, Indications and Usage, Dosage and Administration. DailyMed version 14, effective January 30, 2026 (still current on DailyMed October 27, 2026); read October 27, 2026. DailyMed
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets US prescribing information, Indications and Usage with Limitations of Use, Dosage and Administration, Warnings and Precautions. DailyMed version 19, effective June 18, 2026 (still current on DailyMed October 27, 2026); read October 27, 2026. DailyMed
- US FDA. Drug Shortages database (via openFDA drug/shortages): Rybelsus 3 mg, 7 mg and 14 mg tablets, status To Be Discontinued, posted June 4, 2026, 'These products will be replaced by Ozempic (semaglutide) tablets.' Read October 27, 2026; cited without a link (accessdata.fda.gov).
- Novo Nordisk (the manufacturer). NovoCare Wegovy pricing page and Wegovy Price Guide (US26NC00049, April 2026): self-pay prices for Wegovy injection, Wegovy HD and Wegovy tablets; introductory offer for two monthly fills through December 31, 2026. Read October 27, 2026; not linked (a sales page).
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead